Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
80.48
+0.08 (+0.10%)
Streaming Delayed Price
Updated: 12:01 PM EST, Nov 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
404,568
Open
81.01
Bid (Size)
80.44 (1)
Ask (Size)
80.55 (5)
Prev. Close
80.40
Today's Range
80.40 - 81.90
52wk Range
55.25 - 159.89
Shares Outstanding
93,148,652
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Analyst Ratings for Sarepta Therapeutics
November 21, 2023
Via
Benzinga
ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
November 18, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Performance
YTD
-35.54%
-35.54%
1 Month
-25.24%
-25.24%
3 Month
-32.78%
-32.78%
6 Month
-34.89%
-34.89%
1 Year
-31.27%
-31.27%
More News
Read More
3 Monster Stocks in the Making
November 18, 2023
Via
The Motley Fool
3 Stocks You’ll Regret Not Buying Soon: November 2023
November 16, 2023
Via
InvestorPlace
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
November 15, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
1 Gene Therapy Stock to Buy and Hold for the Long Haul
November 08, 2023
Via
The Motley Fool
Analyst Ratings for Sarepta Therapeutics
November 02, 2023
Via
Benzinga
Why Sarepta Therapeutics Stock Is Crashing Today
October 31, 2023
Via
The Motley Fool
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
November 15, 2023
Via
Benzinga
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
November 15, 2023
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Sarepta Therapeutics Stock a Bad-News Buy?
November 09, 2023
Via
The Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
November 08, 2023
Via
The Motley Fool
SRPT LOSS ALERT: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
November 07, 2023
Via
NewMediaWire
8 Health Care Stocks Whale Activity In Today's Session
November 07, 2023
Via
Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Via
Investor's Business Daily
Sarepta Therapeutics to Present at the UBS Biopharma Conference
November 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
November 02, 2023
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
November 01, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
What's Going On With Biotech Contract Service Firm Catalent Stock Today?
October 31, 2023
Via
Benzinga
Earnings Scheduled For November 1, 2023
November 01, 2023
Via
Benzinga
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
October 31, 2023
Via
Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 31, 2023
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 31, 2023
Via
Benzinga
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
October 31, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.